Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-synthelabo ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-aventis ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

qdoxx pharma ab - tiklopidinhydroklorid - tablett - 250 mg - tiklopidinhydroklorid 250 mg aktiv substans - tiklopidin

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiska medel - förebyggande av venös tromboembolism (vte) hos vuxna patienter som genomgår elektiv höft- eller knäbytesoperation. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 för hemodynamiskt instabila pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 och 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - rivaroxaban - filmdragerad tablett - 2,5 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; rivaroxaban 2,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rivaroxaban - filmdragerad tablett - 2,5 mg - rivaroxaban 2,5 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne